Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
Primary Industries
- Drugs
- Cancer
- Pharmaceuticals
- Therapeutic
- Biotechnology
- Diagnostic
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 5086
License Grant
The Company entered into a license agreement with the Canadian University whereby it obtained an exclusive worldwide license (the CD77 License), with the right to grant sublicenses, to make, have made, use and sell any product using any method of selectively purging CD77 positive cells from bone marrow described in certain U.S. and PCT patent applications (U.S. Patent No. 5,801,145), and to use, have used, make and have made the method for treatment of Non-Hodgkin’s Lymphomas described in such applications (the Licensed CD77 Technology) for the purpose of producing products using the CD77 Technology (Licensed CD77 Products).
Field of Use
Although no assurance can be given, the Licensed CD77 Technology may lead to improved interventions for cancer patients whose therapies include autologous stem cell transplantation (ASCT).
Preliminary research indicates that stem cells may be removed from patients undergoing radiation or chemotherapy, and then transplanted back into the patient using the Licensed CD77 Technology. Shiga-like toxin 1, a bacterial toxin, is used as an agent to selectively kill cancer cells in the patient’s bone marrow without harming the essential marrow cells which allow regeneration of marrow’s capacity for forming blood cells.
IPSCIO Record ID: 3624
License Grant
The Israeli Licensor hereby grants to the Licensee, an exclusive license to exploit in any manner and for any and all purposes the Patent, including the right to grant sublicenses, make, have made, use, market and sell the Products.
License Property
The Company entered into a License Agreement to acquire a License of stem cell expansion technology related to bone marrow transplants. The Company received an exclusive, worldwide License to use the technology over the life of the related patent. The License grants exclusivity over all products, uses and related intellectual property, and grants the Company the right to enter into sub-Licenses. This technology, if fully developed, will offer novel solutions to make procedures like bone marrow transplants and other methods of cell therapy more accessible to patients suffering from leukemia, lymphoma, myeloma and a broad range of complicated diseases and disorders.
IPSCIO Record ID: 3285
License Grant
Licensor grants exclusive rights to develop, commercialize and market Rituxan outside the United States and Canada.
License Property
Rituximabis a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B cells. Rituximab destroys B cells and is therefore used to treat diseases which are characterized by excessive numbers of B cells, overactive B cells, or dysfunctional B cells. This includes many lymphomas, leukemias, transplant rejection, and autoimmune disorders.
Field of Use
RITUXAN® (Rituximab) is indicated for the treatment of
Low-grade or follicular CD20-positive non-Hodgkin's lymphoma as a single-agent therapy in patients whose disease recurred or did not respond to initial treatment
Follicular CD20-positive non-Hodgkin's lymphoma as an initial treatment with chemotherapy, and in patients whose initial treatment was successful, as a single-agent follow-up therapy
Low-grade or follicular CD20-positive non-Hodgkin's lymphoma as a single-agent follow-up therapy for patients who responded to initial treatment with CVP chemotherapy
Low-grade or follicular CD20-positive non-Hodgkin's lymphoma as a single-agent therapy in patients whose disease recurred or did not respond to initial treatment
Follicular CD20-positive non-Hodgkin's lymphoma as an initial treatment with chemotherapy, and in patients whose initial treatment was successful, as a single-agent follow-up therapy
Low-grade or follicular CD20-positive non-Hodgkin's lymphoma as a single-agent follow-up therapy for patients who responded to initial treatment with CVP chemotherapy
IPSCIO Record ID: 27461
License Grant
The agreement is to manufacture developmental, clinical and commercial quantities of anti-CD30 monoclonal antibody, which is a component of ADCETRIS. As part of the agreement the Licensor hereby grants an irrevocable, worldwide, nonexclusive license with the right to grant sublicenses, to each Licensor Invention which has been incorporated into the manufacturing process of the Bulk Drug Substance.
License Property
ADCETRIS®, or brentuximab vedotin, is an antibody-drug conjugate, or ADC, comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing the Licensee's proprietary technology.
The treatment of patients with systemic anaplastic large cell lymphoma (ALCL) after failure of at least one prior multi-agent chemotherapy regimen.
Field of Use
The treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates.
IPSCIO Record ID: 28789
License Grant
The Licensor entered into a License Agreement with the Licensee in relation to EVO 022, EVO 033 and EVO 044. EVO 022 is a combination drug therapy which is focused on the treatment of breast cancer. EVO 033 is a reformulation of an off patent novel anti microtubule agent targeted against breast cancer. EVO 044 utilises a stem cell technology to form bone marrow.
License Property
The Licensor acquires, develops and commercializes drugs to treat a variety of cancers, including pancreatic, renal and small-cell lung cancer.
Field of Use
The Licensee is a Pharmaceutical Company.
IPSCIO Record ID: 26630
License Grant
The Licensor granted Exclusive Marketing rights to the Licensee, for the PLX I technology for therapeutic applications.
Also included in the License are the rights to use the PLX I technology in Stem Cell's in-vitro screening applications, if any, worldwide.
License Property
The PLX I technology means the use of mesenchymal cells derived from placenta (MSCs) and grown in PluriStem Ltd's 3-D microenvironment (including improvements to the microenvironment) for therapeutic indications including bone marrow transplant, stroke and others.
Field of Use
The rights granted apply to the healthcare industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
